Antiretroviral nanoparticles: An extended drug delivery modality

Christopher J. Destache; Michael Goede; Todd Belgum

doi:10.4155/tde.10.42

Antiretroviral nanoparticles: An extended drug delivery modality

Christopher J. Destache, Michael Goede, Todd Belgum

Department of Pharmacy Practice

Research output: Contribution to journal › Article › peer-review

Abstract

The antiretroviral nanoparticle formulation laboratory at Creighton University School of Pharmacy & Health Professions is lead by Chris Destache. Over the past 4 years, this laboratory has been investigating the use of antiretroviral nanoparticles as a sustained drug delivery method for HIV-1-infected patients.

Original language	English (US)
Pages (from-to)	383-386
Number of pages	4
Journal	Therapeutic delivery
Volume	1
Issue number	3
DOIs	https://doi.org/10.4155/tde.10.42
State	Published - Sep 2010

All Science Journal Classification (ASJC) codes

Pharmaceutical Science

Access to Document

10.4155/tde.10.42

Fingerprint Dive into the research topics of 'Antiretroviral nanoparticles: An extended drug delivery modality'. Together they form a unique fingerprint.

Cite this

@article{dd37d74dfe164845b2160a2f25fdab12,

title = "Antiretroviral nanoparticles: An extended drug delivery modality",

abstract = "The antiretroviral nanoparticle formulation laboratory at Creighton University School of Pharmacy & Health Professions is lead by Chris Destache. Over the past 4 years, this laboratory has been investigating the use of antiretroviral nanoparticles as a sustained drug delivery method for HIV-1-infected patients.",

author = "Destache, {Christopher J.} and Michael Goede and Todd Belgum",

year = "2010",

month = sep,

doi = "10.4155/tde.10.42",

language = "English (US)",

volume = "1",

pages = "383--386",

journal = "Therapeutic Delivery",

issn = "2041-5990",

publisher = "Future Science",

number = "3",

}

TY - JOUR

T1 - Antiretroviral nanoparticles

T2 - An extended drug delivery modality

AU - Destache, Christopher J.

AU - Goede, Michael

AU - Belgum, Todd

PY - 2010/9

Y1 - 2010/9

N2 - The antiretroviral nanoparticle formulation laboratory at Creighton University School of Pharmacy & Health Professions is lead by Chris Destache. Over the past 4 years, this laboratory has been investigating the use of antiretroviral nanoparticles as a sustained drug delivery method for HIV-1-infected patients.

AB - The antiretroviral nanoparticle formulation laboratory at Creighton University School of Pharmacy & Health Professions is lead by Chris Destache. Over the past 4 years, this laboratory has been investigating the use of antiretroviral nanoparticles as a sustained drug delivery method for HIV-1-infected patients.

UR - http://www.scopus.com/inward/record.url?scp=79954505080&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79954505080&partnerID=8YFLogxK

U2 - 10.4155/tde.10.42

DO - 10.4155/tde.10.42

M3 - Article

C2 - 22816141

AN - SCOPUS:79954505080

VL - 1

SP - 383

EP - 386

JO - Therapeutic Delivery

JF - Therapeutic Delivery

SN - 2041-5990

IS - 3

ER -

Antiretroviral nanoparticles: An extended drug delivery modality

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Cite this